Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Major Shareholder Purchases $186,389.40 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) major shareholder Innovation Ltd Panacea acquired 19,335 shares of the stock in a transaction that occurred on Thursday, July 17th. The shares were bought at an average price of $9.64 per share, for a total transaction of $186,389.40. Following the transaction, the insider owned 1,350,000 shares of the company's stock, valued at $13,014,000. This trade represents a 1.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Atara Biotherapeutics Price Performance

Shares of ATRA stock traded up $0.18 on Thursday, hitting $12.44. 76,539 shares of the stock traded hands, compared to its average volume of 120,443. The firm has a market cap of $74.15 million, a price-to-earnings ratio of -3.34 and a beta of 0.18. Atara Biotherapeutics, Inc. has a 52 week low of $5.01 and a 52 week high of $18.70. The firm has a 50 day simple moving average of $8.49 and a two-hundred day simple moving average of $8.09.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last posted its earnings results on Thursday, May 15th. The biotechnology company reported $3.50 earnings per share for the quarter, beating the consensus estimate of ($3.07) by $6.57. The company had revenue of $98.10 million for the quarter, compared to analysts' expectations of $4.30 million. Sell-side analysts forecast that Atara Biotherapeutics, Inc. will post -10.39 EPS for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several institutional investors have recently bought and sold shares of the stock. EcoR1 Capital LLC grew its stake in Atara Biotherapeutics by 7.7% during the first quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company's stock valued at $3,405,000 after acquiring an additional 41,049 shares in the last quarter. Staley Capital Advisers Inc. grew its stake in shares of Atara Biotherapeutics by 60.0% in the 1st quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company's stock worth $475,000 after buying an additional 30,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics in the 4th quarter worth $48,000. Cubist Systematic Strategies LLC purchased a new position in shares of Atara Biotherapeutics in the 4th quarter worth $169,000. Finally, Citadel Advisors LLC grew its stake in shares of Atara Biotherapeutics by 2.6% in the 4th quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company's stock worth $3,558,000 after buying an additional 6,873 shares in the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.